—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Jazz Pharmaceuticals PLC (JAZZ) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for JAZZ, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.60 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How JAZZ has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.60 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Jazz Pharmaceuticals PLC moved 0.60% on average · correlation 0.15 · higher than 61% of US names
  • Beta, last 3 months 0.64 about the same as over the year
  • On the 10 worst bond days −0.64% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.60% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against JAZZ on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Jazz Pharmaceuticals PLC

JAZZ in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Jazz Pharmaceuticals identifies, develops and sells prescription medicines, with a portfolio spanning sleep disorders, epilepsy, oncology and haematology. Its marketed products include treatments for narcolepsy, seizure disorders such as Lennox-Gastaut and Dravet syndromes, acute lymphoblastic leukaemia, and several solid-tumour cancers, alongside a pipeline of earlier-stage cancer and neurology candidates. It is headquartered in Dublin and sells across the United States, Europe and other markets.
Where it sits in the stack
Jazz sits outside Closelooknet's technology-focused indices; it belongs to the healthcare sector, within biotechnology, where our universe tracks pharmaceutical companies developing and commercialising branded drugs rather than any AI build-out layer.
Who it is priced against
Closelooknet has not yet built a peer group for Jazz; the diary's closest market comparison is UCB, another company selling both neuroscience and oncology medicines.
Why Closelooknet tracks it
Jazz holds a seat in the Russell 1000 but carries no Closelooknet score, no index seat in Rubin or Halo, and no quotes across our editions so far.
What the diary watches
Whether clinical results for its later-stage oncology candidates, including zanidatamab and dordaviprone, move the read on its pipeline beyond the established sleep and epilepsy franchises.

Jazz Pharmaceuticals PLC (JAZZ) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 8 analyst actions on the wire · latest: price target by Goldman Sachs, 2026-09-24

The Street on this name

Analyst actions and the latest print for JAZZ from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Goldman Sachs — target 337 Target set to $337 (+43.5% to spot) 2026-09-24
  • Price target UBS — target 337 from 315 Target raised to $337 from $315 (+37.4% to spot) 2026-09-11
  • Price target RBC Capital — target 299 from 277 Target raised to $299 from $277 (+20.8% to spot) 2026-08-28

8 actions on the analyst wire since 2026-08-13: 8 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Jazz Pharmaceuticals PLC (JAZZ)?

Jazz Pharmaceuticals PLC trades as JAZZ on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is JAZZ in a Closelooknet index?

Not currently — Jazz Pharmaceuticals PLC is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does JAZZ trade against its moving averages?

Pullback inside an uptrend stack: Trades -4.4% vs the 50-day and +13.2% vs the 200-day average, 10.7% below the 52-week high and +89.2% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Jazz Pharmaceuticals PLC trade when bond yields rise?

Over the past year Jazz Pharmaceuticals PLC had a beta of 0.60 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 61% of US names. On the 10 sessions in which long bonds fell most it moved −0.64% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Jazz Pharmaceuticals PLC do?

Jazz Pharmaceuticals identifies, develops and sells prescription medicines, with a portfolio spanning sleep disorders, epilepsy, oncology and haematology. Its marketed products include treatments for narcolepsy, seizure disorders such as Lennox-Gastaut and Dravet syndromes, acute lymphoblastic leukaemia, and several solid-tumour cancers, alongside a pipeline of earlier-stage cancer and neurology candidates. It is headquartered in Dublin and sells across the United States, Europe and other markets. Closelooknet has not yet built a peer group for Jazz; the diary's closest market comparison is UCB, another company selling both neuroscience and oncology medicines.

Where does Jazz Pharmaceuticals PLC sit in the AI build-out?

Jazz sits outside Closelooknet's technology-focused indices; it belongs to the healthcare sector, within biotechnology, where our universe tracks pharmaceutical companies developing and commercialising branded drugs rather than any AI build-out layer. Jazz holds a seat in the Russell 1000 but carries no Closelooknet score, no index seat in Rubin or Halo, and no quotes across our editions so far.

What has Wall Street done on Jazz Pharmaceuticals PLC recently?

The most recent analyst action on Jazz Pharmaceuticals PLC on the Closelooknet wire is a price target by Goldman Sachs on 2026-09-24 (target 337). 8 actions on the analyst wire since 2026-08-13: 8 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for JAZZ, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.